411 related articles for article (PubMed ID: 23256277)
1. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
2. Prescription drug prices in the US.
Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
[No Abstract] [Full Text] [Related]
3. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
Bell H
Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
[TBL] [Abstract][Full Text] [Related]
4. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
5. [Generic medicines].
Peláez de Loño J
Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
[TBL] [Abstract][Full Text] [Related]
6. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
7. Drug shortages--a critical challenge for the generic-drug market.
Chabner BA
N Engl J Med; 2011 Dec; 365(23):2147-9. PubMed ID: 22040167
[No Abstract] [Full Text] [Related]
8. Medicine. Shortages of cancer drugs put patients, trials at risk.
Kaiser J
Science; 2011 Apr; 332(6029):523. PubMed ID: 21527686
[No Abstract] [Full Text] [Related]
9. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Sarpatwari A; Avorn J; Kesselheim AS
JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
[No Abstract] [Full Text] [Related]
10. RX for nosebleed prices.
Greenwald J
Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
[No Abstract] [Full Text] [Related]
11. How the US Food and Drug Administration can solve the prescription drug shortage problem.
Schweitzer SO
Am J Public Health; 2013 May; 103(5):e10-4. PubMed ID: 23488502
[TBL] [Abstract][Full Text] [Related]
12. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
13. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: cost savings.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
[No Abstract] [Full Text] [Related]
15. Broken drug markets in infectious diseases: Opportunities outside the private sector?
Alpern JD; Dunlop SJ; Stauffer WM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007190. PubMed ID: 30973876
[TBL] [Abstract][Full Text] [Related]
16. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
Gudiksen KL; King JS
J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
[No Abstract] [Full Text] [Related]
17. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
Fogel LE; Ray CJ
Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
[TBL] [Abstract][Full Text] [Related]
18. Shades of gray. Secondary drug distributors raise questions.
Lee J
Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
[No Abstract] [Full Text] [Related]
19. America's drug problem.
Philpott S
Hastings Cent Rep; 2012; 42(4):9-10. PubMed ID: 22777971
[No Abstract] [Full Text] [Related]
20. Is India ready to lead the battle for fair access to medicines?
Lancet Oncology
Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
